MX2022013809A - Proteinas de fusion para inmunoterapia contra cancer y enfermedades infecciosas. - Google Patents
Proteinas de fusion para inmunoterapia contra cancer y enfermedades infecciosas.Info
- Publication number
- MX2022013809A MX2022013809A MX2022013809A MX2022013809A MX2022013809A MX 2022013809 A MX2022013809 A MX 2022013809A MX 2022013809 A MX2022013809 A MX 2022013809A MX 2022013809 A MX2022013809 A MX 2022013809A MX 2022013809 A MX2022013809 A MX 2022013809A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- fusion proteins
- binding domain
- cathepsin
- infectious diseases
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 208000035473 Communicable disease Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 101150013553 CD40 gene Proteins 0.000 abstract 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 4
- 102000004172 Cathepsin L Human genes 0.000 abstract 3
- 108090000624 Cathepsin L Proteins 0.000 abstract 3
- 102000004961 Furin Human genes 0.000 abstract 3
- 108090001126 Furin Proteins 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 3
- 230000007017 scission Effects 0.000 abstract 3
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000005945 translocation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen proteínas de fusión para inmunoterapia contra el cáncer y enfermedades infecciosas. Una proteína de fusión de acuerdo con la invención comprende un dominio de unión a CD40; un antígeno; y un dominio de translocación situado entre el dominio de unión a CD40 y el antígeno, en el que un sitio de escisión de furina y/o catepsina está presente en la proteína de fusión entre el dominio de unión a CD40 y el dominio de translocación. El antígeno es un antígeno de un patógeno o un antígeno tumoral. El sitio de escisión de furina y/o catepsina L permite la eliminación del dominio de unión a CD40 la proteína de fusión a través de la escisión de furina y/o catepsina L. También se describen composiciones farmacéuticas, vectores de expresión y uso de las proteínas de fusión de la invención para inducir una respuesta inmunitaria mediada por células específicas de antígeno, tratar un tumor y/o una enfermedad provocada por un patógeno en un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020545P | 2020-05-06 | 2020-05-06 | |
| PCT/US2021/029203 WO2021225820A1 (en) | 2020-05-06 | 2021-04-26 | Fusion proteins for immunotherapy against cancer and infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013809A true MX2022013809A (es) | 2022-11-30 |
Family
ID=78412282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013809A MX2022013809A (es) | 2020-05-06 | 2021-04-26 | Proteinas de fusion para inmunoterapia contra cancer y enfermedades infecciosas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210347906A1 (es) |
| EP (1) | EP4146701A4 (es) |
| JP (1) | JP2023524814A (es) |
| KR (1) | KR20230008162A (es) |
| CN (1) | CN115956086A (es) |
| AU (1) | AU2021268885A1 (es) |
| BR (1) | BR112022021797A2 (es) |
| CA (1) | CA3172293A1 (es) |
| IL (1) | IL296880A (es) |
| MX (1) | MX2022013809A (es) |
| TW (1) | TWI817113B (es) |
| WO (1) | WO2021225820A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240141016A1 (en) * | 2021-11-05 | 2024-05-02 | Navicure Biopharmaceuticals Limited | Immunogenic fusion proteins against infectious animal diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295502A1 (en) * | 2002-11-12 | 2004-06-03 | Yucheng Chang | Adenoviral vector vaccine |
| CA3092223C (en) * | 2008-07-21 | 2023-01-03 | Apogenix Ag | Tnfsf single chain molecules |
| CN109535228B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| WO2014121099A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| ES2919749T3 (es) * | 2014-06-11 | 2022-07-28 | Molecular Templates Inc | Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa |
| BR112017018017A2 (pt) * | 2015-02-26 | 2018-04-10 | Thevax Genetics Vaccine Co Ltd | composição de vacina compreendendo uma proteína imunogênica e adjuvantes de combinação para uso na promoção de respostas de células t específicas de antigenos |
| EP3603661A3 (en) * | 2015-04-22 | 2020-04-01 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| CN107771184B (zh) * | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | 针对cd40的抗体 |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN109715651A (zh) * | 2016-09-19 | 2019-05-03 | 生控基因疫苗股份有限公司 | 乙型肝炎治疗型疫苗 |
| WO2018213747A1 (en) * | 2017-05-19 | 2018-11-22 | Merrimack Pharmaceuticals, Inc. | 4-1bb agonist and cd40 agonist bispecific molecules |
-
2021
- 2021-04-26 EP EP21799774.1A patent/EP4146701A4/en active Pending
- 2021-04-26 CA CA3172293A patent/CA3172293A1/en active Pending
- 2021-04-26 IL IL296880A patent/IL296880A/en unknown
- 2021-04-26 BR BR112022021797A patent/BR112022021797A2/pt unknown
- 2021-04-26 US US17/240,160 patent/US20210347906A1/en active Pending
- 2021-04-26 MX MX2022013809A patent/MX2022013809A/es unknown
- 2021-04-26 JP JP2022567573A patent/JP2023524814A/ja active Pending
- 2021-04-26 WO PCT/US2021/029203 patent/WO2021225820A1/en unknown
- 2021-04-26 CN CN202180029571.6A patent/CN115956086A/zh active Pending
- 2021-04-26 KR KR1020227042378A patent/KR20230008162A/ko active Search and Examination
- 2021-04-26 AU AU2021268885A patent/AU2021268885A1/en active Pending
- 2021-05-04 TW TW110116026A patent/TWI817113B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI817113B (zh) | 2023-10-01 |
| JP2023524814A (ja) | 2023-06-13 |
| EP4146701A4 (en) | 2024-05-15 |
| CN115956086A (zh) | 2023-04-11 |
| KR20230008162A (ko) | 2023-01-13 |
| TW202200625A (zh) | 2022-01-01 |
| EP4146701A1 (en) | 2023-03-15 |
| AU2021268885A1 (en) | 2022-10-27 |
| BR112022021797A2 (pt) | 2022-12-13 |
| US20210347906A1 (en) | 2021-11-11 |
| CA3172293A1 (en) | 2021-11-11 |
| WO2021225820A1 (en) | 2021-11-11 |
| IL296880A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display | |
| Duarte et al. | Generation of immunity against pathogens via single-domain antibody–antigen constructs | |
| Sewell et al. | Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7 | |
| BR112021018694A2 (pt) | Vesículas extracelulares para distribuição de vacina | |
| Henriques et al. | Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge | |
| CY1118801T1 (el) | Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου | |
| Chua et al. | Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2 | |
| Shukla et al. | Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform | |
| US11352416B2 (en) | Mosaic chimeric viral vaccine particle | |
| Venuti et al. | Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| MX2022013809A (es) | Proteinas de fusion para inmunoterapia contra cancer y enfermedades infecciosas. | |
| Wolkers et al. | Optimizing the efficacy of epitope-directed DNA vaccination | |
| Song et al. | Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment | |
| Masuko et al. | Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy | |
| AU2018359358B2 (en) | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines | |
| JP5778666B2 (ja) | タンパク質複合体の精製方法 | |
| Song et al. | Cancer immunotherapy using a potent immunodominant CTL epitope | |
| Dong et al. | Direct loading of iTEP-delivered CTL epitope onto MHC class I complexes on the dendritic cell surface | |
| US10660949B2 (en) | Vaccination using plant virus particles linked to HER2 antigens | |
| Starodubova et al. | C-terminal lysosome targeting domain of CD63 modifies cellular localization of rabies virus glycoprotein | |
| Talebi et al. | Immuno-stimulating peptide derived from HMGB1 is more effective than the N-terminal domain of Gp96 as an endogenous adjuvant for improvement of protein vaccines | |
| Xv et al. | Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein | |
| Mashhadi Abolghasem Shirazi et al. | Immunoinformatics Approach for Designing an HPV Epitope-Based Vaccine Candidate Harboring Built-in Adjuvants | |
| Durrant et al. | Principles of cancer treatment by immunotherapy |